Am. J. Respir. Crit. Care Med., Volume 164, Number 9, November 2001, 1633-1639

Effect of Wortmannin on Human Eosinophil Responses in Vitro and on Bronchial Inflammation and Airway Hyperresponsiveness in Guinea Pigs in Vivo

CHARLES I. EZEAMUZIE, JALAJA SUKUMARAN, and ELIZABETH PHILIPS

Department of Pharmacology and Toxicology, Faculty of Medicine, Kuwait University, Safat, Kuwait

Many mediators activate eosinophils via transduction pathways involving the enzyme phosphatidylinositol 3-kinase. The initial investigation of wortmannin, a specific inhibitor of PI3-kinase, was of its effect on human and guinea pig eosinophil superoxide (O₂) release and degranulation in vitro. Subsequently, the effect on allergen- and Sephadex-induced bronchial inflammation and airway hyperresponsiveness (AHR) in vivo in guinea pigs was investigated. Wortmannin potently inhibited complement C5a-induced O₂ generation and eosinophil peroxidase (EPO) release from human eosinophils, with 50% inhibition produced by a 1-10 nM concentration. Both aerosol allergen challenge of sensitized guinea pigs and intravenous injection of Sephadex beads in normal guinea pigs caused, in 24 h, significant eosinophilia and increased EPO activity in bronchoalveolar lavage fluid (BALF) and AHR to intravenous acetylcholine and histamine. In the allergic model, intranasal pretreatment with wortmannin had no effect on BALF eosinophilia, but dose dependently inhibited BALF EPO activity. At 1 mg/kg, the drug abolished the AHR to histamine, but not acetylcholine. In the Sephadex model, the drug significantly inhibited all three parameters (eosinophilia, increased EPO activity, and AHR to both spasmogens). These results show that wortmannin is a potent inhibitor of human eosinophil degranulation and that when administered intranasally can prevent AHR in allergen-challenged guinea pigs, probably by inhibiting eosinophil degranulation, but not their accumulation in BALF. This may be relevant to the possible clinical utility of wortmannin in conditions involving eosinophilic inflammation and AHR.

This article has been cited by other articles:

				J. A. Marwick, Kian Fan Chung, and I. M. Adcock Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease Therapeutic Advances in Respiratory Disease, February 1, 2010; 4(1): 19 - 34. [Abstract] [PDF]

				H. S. M. Farghaly, I. S. Blagbrough, D. A. Medina-Tato, and M. L. Watson Interleukin 13 Increases Contractility of Murine Tracheal Smooth Muscle by a Phosphoinositide 3-kinase p110{delta}-Dependent Mechanism Mol. Pharmacol., May 1, 2008; 73(5): 1530 - 1537. [Abstract] [Full Text] [PDF]

				V. Pinho, R. de Castro Russo, F. A. Amaral, L. P. de Sousa, M. M. Barsante, D. G. de Souza, J. C. Alves-Filho, D. C. Cara, J. S. Hayflick, C. Rommel, et al. Tissue- and Stimulus-Dependent Role of Phosphatidylinositol 3-Kinase Isoforms for Neutrophil Recruitment Induced by Chemoattractants In Vivo J. Immunol., December 1, 2007; 179(11): 7891 - 7898. [Abstract] [Full Text] [PDF]

				S. R. Kim, K. S. Lee, S. J. Park, K. H. Min, K. Y. Lee, Y. H. Choe, Y. R. Lee, J. S. Kim, S. J. Hong, and Y. C. Lee PTEN Down-Regulates IL-17 Expression in a Murine Model of Toluene Diisocyanate-Induced Airway Disease J. Immunol., November 15, 2007; 179(10): 6820 - 6829. [Abstract] [Full Text] [PDF]

				K. Ito, G. Caramori, and I. M. Adcock Therapeutic Potential of Phosphatidylinositol 3-Kinase Inhibitors in Inflammatory Respiratory Disease J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 1 - 8. [Abstract] [Full Text] [PDF]

				K. S. Lee, S. R. Kim, S. J. Park, H. K. Lee, H. S. Park, K. H. Min, S. M. Jin, and Y. C. Lee Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN) Reduces Vascular Endothelial Growth Factor Expression in Allergen-Induced Airway Inflammation Mol. Pharmacol., June 1, 2006; 69(6): 1829 - 1839. [Abstract] [Full Text] [PDF]

				K. S. Lee, H. K. Lee, J. S. Hayflick, Y. C. Lee, and K. D. Puri Inhibition of phosphoinositide 3-kinase {delta} attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model FASEB J, March 1, 2006; 20(3): 455 - 465. [Abstract] [Full Text] [PDF]

				V. Pinho, D. G. Souza, M. M. Barsante, F. P. Hamer, M. S. De Freitas, A. G. Rossi, and M. M. Teixeira Phosphoinositide-3 kinases critically regulate the recruitment and survival of eosinophils in vivo: importance for the resolution of allergic inflammation J. Leukoc. Biol., May 1, 2005; 77(5): 800 - 810. [Abstract] [Full Text] [PDF]

				S. Myou, A. R. Leff, S. Myo, E. Boetticher, J. Tong, A. Y. Meliton, J. Liu, N. M. Munoz, and X. Zhu Blockade of Inflammation and Airway Hyperresponsiveness in Immune-sensitized Mice by Dominant-Negative Phosphoinositide 3-Kinase-TAT J. Exp. Med., November 17, 2003; 198(10): 1573 - 1582. [Abstract] [Full Text] [PDF]

				S. Myou, X. Zhu, S. Myo, E. Boetticher, A. Y. Meliton, J. Liu, N. M. Munoz, and A. R. Leff Blockade of Airway Inflammation and Hyperresponsiveness by HIV-TAT-Dominant Negative Ras J. Immunol., October 15, 2003; 171(8): 4379 - 4384. [Abstract] [Full Text] [PDF]

				W. Duan, I. C. Kuo, S. Selvarajan, K. Y. Chua, B. H. Bay, and W. S. F. Wong Antiinflammatory Effects of Genistein, a Tyrosine Kinase Inhibitor, on a Guinea Pig Model of Asthma Am. J. Respir. Crit. Care Med., January 15, 2003; 167(2): 185 - 192. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Asthma, Airway Biology, and Nasal Disorders in AJRCCM 2001 Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 598 - 618. [Full Text] [PDF]